Bi-layer tablets are under-utilized despite the advantages they offer over monolayer forms.

Formulating Tablets Layer by Layer

A fixed-dose combination tablet was prepared by a quality-by-design approach using two-level factorial design.

Using QbD to Develop Fixed-Dose Combination Tablets 

Topic

Articles

The companies collaborate to develop and commercialize ARV-471, an investigational oral PROTAC (proteolysis targeting chimeras) estrogen receptor protein degrader.

Pfizer and Arvinas to Develop and Commercialize Estrogen Receptor Targeting Breast Cancer 

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Modeling the manufacturing process benefits both development and operations. 

GSK Pilots Digital Twin for Vaccine Manufacturing 

The US federal government awarded new funding to the National Institute for Innovation in Manufacturing Biopharmaceuticals, including funding under the American Rescue Plan that will be used to advance vaccine manufacturing. 

NIIMBL Receives Federal Funding for Biopharmaceutical Manufacturing Projects

The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.

Continuus Pharmaceuticals Opens Process Development Lab

Eli Lilly and Company has announced its acquisition of biotech firm Protomer Technologies, giving it a protein-engineering platform for next-generation protein therapeutics.

Lilly Acquires Protomer Technologies in Potential $1-Billion Deal

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.

Sparx Therapeutics to Build Commercial Antibody Manufacturing Facility in China

GlaxoSmithKline and Alector have partnered to co-develop two mAbs for a range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.

GSK and Alector Collaborate on Neurodegenerative Disease mAb Candidates

The collaboration continues as the companies design bioprocess impurity reagent sets to detect residual HCP from HEK 293 cells. 

Gyros Protein Technologies and Cygnus Technologies to Develop Impurity Reagent Sets

Feliza Mirasol is the science editor for 

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.